Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy

V. Iodice, K. Kimpinski, S. Vernino, P. Sandroni, R. D. Fealey, Phillip Anson Low

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

OBJECTIVE:: To evaluate the efficacy of immunotherapy in the treatment of patients with seropositive and seronegative putative autoimmune autonomic ganglionopathy (AAG) using validated autonomic function tests and instruments. BACKGROUND:: AAG is an immune-mediated disorder characterized by prominent and selective involvement of autonomic nerve fibers or ganglia. Treatment with IV immunoglobulin (IVIg) or plasma exchange (PE) has been reported to be effective in single case reports. METHODS:: We studied six patients, four with seropositive and two with seronegative putative AAG, who underwent autonomic function tests and completed two validated questionnaires, to assess autonomic symptoms before and after immunomodulatory treatment. Patients were treated with standard doses of IVIg, PE, or immunosuppressants in a specific sequential therapy protocol depending on clinical response. RESULTS:: Of the six patients (all women, mean ages 49.3 ± 10.6 years), four patients were ganglionic (α3) AChR autoantibody positive and two were autoantibody negative. All patients showed clinical improvement after treatment. Sudomotor function assessed by quantitative sudomotor axon reflex test and thermoregulatory sweat test improved in four patients after treatment. CONCLUSIONS:: Immunomodulatory treatment can be effective in both seropositive and seronegative putative autoimmune autonomic ganglionopathy. Plasma exchange or combined therapy with immunosuppressive agents should be considered in patients who do not benefit from IV immunoglobulin alone.

Original languageEnglish (US)
Pages (from-to)2002-2008
Number of pages7
JournalNeurology
Volume72
Issue number23
DOIs
StatePublished - Jun 9 2009

Fingerprint

Immunotherapy
Plasma Exchange
Intravenous Immunoglobulins
Therapeutics
Immunosuppressive Agents
Autoantibodies
Autonomic Ganglia
Autonomic Pathways
Sweat
Immune System Diseases
Nerve Fibers
Axons
Reflex

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. / Iodice, V.; Kimpinski, K.; Vernino, S.; Sandroni, P.; Fealey, R. D.; Low, Phillip Anson.

In: Neurology, Vol. 72, No. 23, 09.06.2009, p. 2002-2008.

Research output: Contribution to journalArticle

Iodice, V. ; Kimpinski, K. ; Vernino, S. ; Sandroni, P. ; Fealey, R. D. ; Low, Phillip Anson. / Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. In: Neurology. 2009 ; Vol. 72, No. 23. pp. 2002-2008.
@article{2fdb62a5062c48e7977871903b573d77,
title = "Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy",
abstract = "OBJECTIVE:: To evaluate the efficacy of immunotherapy in the treatment of patients with seropositive and seronegative putative autoimmune autonomic ganglionopathy (AAG) using validated autonomic function tests and instruments. BACKGROUND:: AAG is an immune-mediated disorder characterized by prominent and selective involvement of autonomic nerve fibers or ganglia. Treatment with IV immunoglobulin (IVIg) or plasma exchange (PE) has been reported to be effective in single case reports. METHODS:: We studied six patients, four with seropositive and two with seronegative putative AAG, who underwent autonomic function tests and completed two validated questionnaires, to assess autonomic symptoms before and after immunomodulatory treatment. Patients were treated with standard doses of IVIg, PE, or immunosuppressants in a specific sequential therapy protocol depending on clinical response. RESULTS:: Of the six patients (all women, mean ages 49.3 ± 10.6 years), four patients were ganglionic (α3) AChR autoantibody positive and two were autoantibody negative. All patients showed clinical improvement after treatment. Sudomotor function assessed by quantitative sudomotor axon reflex test and thermoregulatory sweat test improved in four patients after treatment. CONCLUSIONS:: Immunomodulatory treatment can be effective in both seropositive and seronegative putative autoimmune autonomic ganglionopathy. Plasma exchange or combined therapy with immunosuppressive agents should be considered in patients who do not benefit from IV immunoglobulin alone.",
author = "V. Iodice and K. Kimpinski and S. Vernino and P. Sandroni and Fealey, {R. D.} and Low, {Phillip Anson}",
year = "2009",
month = "6",
day = "9",
doi = "10.1212/WNL.0b013e3181a92b52",
language = "English (US)",
volume = "72",
pages = "2002--2008",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy

AU - Iodice, V.

AU - Kimpinski, K.

AU - Vernino, S.

AU - Sandroni, P.

AU - Fealey, R. D.

AU - Low, Phillip Anson

PY - 2009/6/9

Y1 - 2009/6/9

N2 - OBJECTIVE:: To evaluate the efficacy of immunotherapy in the treatment of patients with seropositive and seronegative putative autoimmune autonomic ganglionopathy (AAG) using validated autonomic function tests and instruments. BACKGROUND:: AAG is an immune-mediated disorder characterized by prominent and selective involvement of autonomic nerve fibers or ganglia. Treatment with IV immunoglobulin (IVIg) or plasma exchange (PE) has been reported to be effective in single case reports. METHODS:: We studied six patients, four with seropositive and two with seronegative putative AAG, who underwent autonomic function tests and completed two validated questionnaires, to assess autonomic symptoms before and after immunomodulatory treatment. Patients were treated with standard doses of IVIg, PE, or immunosuppressants in a specific sequential therapy protocol depending on clinical response. RESULTS:: Of the six patients (all women, mean ages 49.3 ± 10.6 years), four patients were ganglionic (α3) AChR autoantibody positive and two were autoantibody negative. All patients showed clinical improvement after treatment. Sudomotor function assessed by quantitative sudomotor axon reflex test and thermoregulatory sweat test improved in four patients after treatment. CONCLUSIONS:: Immunomodulatory treatment can be effective in both seropositive and seronegative putative autoimmune autonomic ganglionopathy. Plasma exchange or combined therapy with immunosuppressive agents should be considered in patients who do not benefit from IV immunoglobulin alone.

AB - OBJECTIVE:: To evaluate the efficacy of immunotherapy in the treatment of patients with seropositive and seronegative putative autoimmune autonomic ganglionopathy (AAG) using validated autonomic function tests and instruments. BACKGROUND:: AAG is an immune-mediated disorder characterized by prominent and selective involvement of autonomic nerve fibers or ganglia. Treatment with IV immunoglobulin (IVIg) or plasma exchange (PE) has been reported to be effective in single case reports. METHODS:: We studied six patients, four with seropositive and two with seronegative putative AAG, who underwent autonomic function tests and completed two validated questionnaires, to assess autonomic symptoms before and after immunomodulatory treatment. Patients were treated with standard doses of IVIg, PE, or immunosuppressants in a specific sequential therapy protocol depending on clinical response. RESULTS:: Of the six patients (all women, mean ages 49.3 ± 10.6 years), four patients were ganglionic (α3) AChR autoantibody positive and two were autoantibody negative. All patients showed clinical improvement after treatment. Sudomotor function assessed by quantitative sudomotor axon reflex test and thermoregulatory sweat test improved in four patients after treatment. CONCLUSIONS:: Immunomodulatory treatment can be effective in both seropositive and seronegative putative autoimmune autonomic ganglionopathy. Plasma exchange or combined therapy with immunosuppressive agents should be considered in patients who do not benefit from IV immunoglobulin alone.

UR - http://www.scopus.com/inward/record.url?scp=67649484456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649484456&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181a92b52

DO - 10.1212/WNL.0b013e3181a92b52

M3 - Article

VL - 72

SP - 2002

EP - 2008

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 23

ER -